Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy

被引:335
作者
Bendle, Gavin M. [1 ]
Linnemann, Carsten [1 ]
Hooijkaas, Anna I. [1 ]
Bies, Laura [1 ]
de Witte, Moniek A. [1 ]
Jorritsma, Annelies [1 ]
Kaiser, Andrew D. M. [1 ]
Pouw, Nadine [2 ]
Debets, Reno [2 ]
Kieback, Elisa [3 ]
Uckert, Wolfgang [3 ]
Song, Ji-Ying [4 ]
Haanen, John B. A. G. [1 ,5 ]
Schumacher, Ton N. M. [1 ]
机构
[1] Netherlands Canc Inst, Div Immunol, NL-1066 CX Amsterdam, Netherlands
[2] Erasmus MC Daniel den Hoed Canc Ctr, Lab Expt Tumor Immunol, Dept Med Oncol, Rotterdam, Netherlands
[3] Max Delbruck Ctr Mol Med, Berlin, Germany
[4] Netherlands Canc Inst, Div Expt Anim Pathol, NL-1066 CX Amsterdam, Netherlands
[5] Netherlands Canc Inst, Div Med Oncol, NL-1066 CX Amsterdam, Netherlands
关键词
ENHANCED ANTITUMOR-ACTIVITY; BONE-MARROW FAILURE; CANCER REGRESSION; TUMOR-REGRESSION; TCR-ALPHA; LYMPHOCYTES; IMMUNOTHERAPY; BETA; MELANOMA; ANTIGEN;
D O I
10.1038/nm.2128
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
070307 [化学生物学]; 071010 [生物化学与分子生物学];
摘要
The transfer of T cell receptor (TCR) genes can be used to induce immune reactivity toward defined antigens to which endogenous T cells are insufficiently reactive. This approach, which is called TCR gene therapy, is being developed to target tumors and pathogens, and its clinical testing has commenced in patients with cancer. In this study we show that lethal cytokine-driven autoimmune pathology can occur in mouse models of TCR gene therapy under conditions that closely mimic the clinical setting. We show that the pairing of introduced and endogenous TCR chains in TCR gene-modified T cells leads to the formation of self-reactive TCRs that are responsible for the observed autoimmunity. Furthermore, we demonstrate that adjustments in the design of gene therapy vectors and target T cell populations can be used to reduce the risk of TCR gene therapy-induced autoimmune pathology.
引用
收藏
页码:565 / U98
页数:7
相关论文
共 41 条
[1]
Transfusion-associated graft-versus-host disease in immunocompetent patients: case series and review of the literature [J].
Agbaht, Kemal ;
Altintas, Neriman Defne ;
Topeli, Arzu ;
Gokoz, Ozay ;
Ozcebe, Osman .
TRANSFUSION, 2007, 47 (08) :1405-1411
[2]
Preclinical development of T cell receptor gene therapy [J].
Bendle, Gavin M. ;
Haanen, John B. A. G. ;
Schumacher, Ton N. M. .
CURRENT OPINION IN IMMUNOLOGY, 2009, 21 (02) :209-214
[3]
A mouse model of lymphocyte infusion-induced bone marrow failure [J].
Bloom, ML ;
Wolk, AG ;
Simon-Stoos, KL ;
Bard, JS ;
Chen, J ;
Young, NS .
EXPERIMENTAL HEMATOLOGY, 2004, 32 (12) :1163-1172
[4]
Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond [J].
Cohen, Cyrille J. ;
Li, Yong F. ;
El-Gamil, Mona ;
Robbins, Paul F. ;
Rosenberg, Steven A. ;
Morgan, Richard A. .
CANCER RESEARCH, 2007, 67 (08) :3898-3903
[5]
Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability [J].
Cohen, Cyrille J. ;
Zhao, Yangbing ;
Zheng, Zhili ;
Rosenberg, Steven A. ;
Morgan, Richard A. .
CANCER RESEARCH, 2006, 66 (17) :8878-8886
[6]
Requirements for effective antitumor responses of TCR transduced T cells [J].
de Witte, Moniek A. ;
Jorritsma, Annelies ;
Kaiser, Andrew ;
van den Boom, Marly D. ;
Dokter, Maarten ;
Bendle, Gavin M. ;
Haanen, John B. A. G. ;
Schumacher, Ton N. M. .
JOURNAL OF IMMUNOLOGY, 2008, 181 (07) :5128-5136
[7]
TCR gene therapy of spontaneous prostate carcinoma requires in vivo T cell activation [J].
de Witte, Moniek A. ;
Bendle, Gavin M. ;
van den Boom, Marly D. ;
Coccoris, Miriam ;
Schell, Todd D. ;
Tevethia, Satvir S. ;
van Tinteren, Harm ;
Mesman, Elly M. ;
Song, Ji-Ying ;
Schumacher, Ton N. M. .
JOURNAL OF IMMUNOLOGY, 2008, 181 (04) :2563-2571
[8]
Targeting self-antigens through allogeneic TCR gene transfer [J].
de Witte, Moniek A. ;
Coccoris, Miriam ;
Wolkers, Monika C. ;
van den Boom, Marly D. ;
Mesman, Elly M. ;
Song, Ji-Ying ;
van der Valk, Martin ;
Haanen, John B. A. G. ;
Schumacher, Ton N. M. .
BLOOD, 2006, 108 (03) :870-877
[9]
Gattinoni L, 2005, J CLIN INVEST, V115, P1616, DOI 10.1172/JCI24480
[10]
Adoptive immunotherapy for cancer: building on success [J].
Gattinoni, L ;
Powell, DJ ;
Rosenberg, SA ;
Restifo, NP .
NATURE REVIEWS IMMUNOLOGY, 2006, 6 (05) :383-393